Editorial Board
Rolf A. Stahel(International Breast Cancer Study Group), Giuseppe Curigliano(European Institute of Oncology), Jacek Jassem(Gdańsk Medical University), Josep Tabernero(Deaconess Hospital), Raffaele Califano(The Christie NHS Foundation Trust), Stefan Bielack(Olgahospital), Paolo G. Casali(Fondazione IRCCS Istituto Nazionale dei Tumori), J Rieß(Hospital Clínico Universitario de Valencia), Tim Eisen(Royal Marsden Hospital), Dario Trapani(Harvard University), Georg Lenz(Charité - Universitätsmedizin Berlin), Stefan Aebi(University of Lucerne), Robert J. Mayer(Applied Natural Sciences), Jordi Remón(Vall d'Hebron Hospital Universitari), Susana Banerjee(Royal Marsden NHS Foundation Trust), Mengyang Di(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Joaquim Bellmunt(Dana-Farber Cancer Institute), Mitchell C. Posner(University Hospital Münster), Jordi Bruix(Hospital Clínic de Barcelona), Andrés Cervantes(INCLIVA Health Research Institute), U Cardoso(European Institute of Oncology), Italy Dittrich(University Hospital Münster), U Hutchings(European Institute of Oncology), Poland(European Institute of Oncology), U Sclafani(University Hospital Münster), C. Sessa(Vita-Salute San Raffaele University), Italy Chan(Ripamonti), Spain Tamura(Ripamonti), Patrick Tan(SingHealth), Hong Kong(European Institute of Oncology)
Cited by 0
Related Papers
Management of Hepatocellular Carcinoma: An Update Δσ
|Hepatology|2011|8.1k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Management of Hepatocellular Carcinoma *
|Hepatology|2005|5.9k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
|Journal of Hepatology|2001|4.1k